Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)
NCT ID: NCT02400788
Last Updated: 2018-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
179 participants
INTERVENTIONAL
2013-04-30
2016-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Radiofrequency Ablation Accompanied With Spontaneous Sorafenib in Early to Intermediate Stage HCC
NCT02187081
Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)
NCT00946153
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
NCT01033240
Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
NCT01900002
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
NCT02834780
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Resminostat + Sorafenib
oral administration
Resminostat
Sorafenib
Sorafenib
oral administration
Sorafenib
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Resminostat
Sorafenib
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with ECOG PS of 0-1
* Patients who can be treated with oral medications and have no gastrointestinal function disorder which is considered to affect the absorption of medications
Exclusion Criteria
* Pregnant women and lactating mothers
* Patients with brain metastases or suspected brain metastases based on the clinical symptoms
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yakult Honsha Co., LTD
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chiba, , Japan
Ishikawa, , Japan
Kanagawa, , Japan
Kochi, , Japan
Kyoto, , Japan
Osaka, , Japan
Saga, , Japan
Shizuoka, , Japan
Tokyo, , Japan
Busan, , South Korea
Daegu, , South Korea
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YHI-1001-HCC-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.